Reverse epidemiology in different stages of heart failure

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 216-224

  Guder G ^a   Gelbrich, G ^a,b   Edelmann, F ^c,d   Wachter, R ^c   Pieske, B ^d,e   Pankuweit, S ^f   Maisch, B ^f   Prettin, C ^g   Brenner, S ^a   Morbach, C ^a   Berliner, D ^a,h   Deubner, N ^a,i   Ertl, G ^a   Angermann, C E ^a   Stork S ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ KERCKHOFF HEART CENTER   (Germany)

Author keywords

AHA ACC stages of heart failure; Prognosis; Reverse epidemiology

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REVERSE EPIDEMIOLOGY; RISK FACTOR; SEX RATIO; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84929354435     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.009     Document Type: Article

References (53)

1. K. Kalantar-Zadeh, G. Block, M.H. Humphreys, J.D. Kopple, Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients, Kidney Int. 63 (2003) 793-808.
2. K. Kalantar-Zadeh, G. Block, T. Horwich, G.C. Fonarow, Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure, J. Am. Coll. Cardiol. 43 (2004) 1439-1444.
3. T.B. Horwich, G.C. Fonarow, Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS, Semin. Dial. 20 (2007) 549-553.
4. A. Oreopoulos, R. Padwal, K. Kalantar-Zadeh, G.C. Fonarow, C.M. Norris, F.A. McAlister, Body mass index and mortality in heart failure: A meta-analysis, Am. Heart J. 156 (2008) 13-22.
5. N.W. Levin, G.J. Handelman, J. Coresh, F.K. Port, G.A. Kaysen, Reverse epidemiology: A confusing, confounding, and inaccurate term, Semin. Dial. 20 (2007) 586-592.
6. J.B. Braunstein, G.F. Anderson, G. Gerstenblith, W. Weller, M. Niefeld, R. Herbert, et al., Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure, J. Am. Coll. Cardiol. 42 (2003) 1226-1233.
7. A. Habbu, N.M. Lakkis, H. Dokainish, The obesity paradox: fact or fiction? Am. J. Cardiol. 98 (2006) 944-948.
8. M. Rauchhaus, A.J. Coats, S.D. Anker, The endotoxin-lipoprotein hypothesis, Lancet 356 (2000) 930-933.
9. K. Kalantar-Zadeh, T.A. Ikizler, G. Block, M.M. Avram, J.D. Kopple, Malnutritioninflammation complex syndrome in dialysis patients: causes and consequences, Am. J. Kidney Dis. 42 (2003) 864-881.
10. C.E. Hastie, S. Padmanabhan, R. Slack, A.C. Pell, K.G. Oldroyd, A.D. Flapan, et al., Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention, Eur. Heart J. 31 (2009) 222-226.
11. S. Uretsky, F.H. Messerli, S. Bangalore, A. Champion, R.M. Cooper-Dehoff, Q. Zhou, et al., Obesity paradox in patients with hypertension and coronary artery disease, Am. J. Med. 120 (2007) 863-870.
12. A.O. Badheka, A. Rathod, M.A. Kizilbash, N. Garg, T. Mohamad, L. Afonso, et al., Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox, Am. J. Med. 123 (2011) 646-651.
13. F. Mehrhof, M. Loffler, G. Gelbrich, C. Ozcelik, M. Posch, H.W. Hense, et al., A network against failing hearts-introducing the German "Competence Network Heart Failure", Int. J. Cardiol. 145 (2010) 135-138.
14. F. Edelmann, R. Stahrenberg, F. Polzin, A. Kockskamper, H.D. Dungen, A. Duvinage, et al., Impaired physical quality of life in patients with diastolic dysfunction associatesmore stronglywith neurohumoral activation thanwith echocardiographic parameters: quality of life in diastolic dysfunction, Am. Heart J. 161 (2011) 797-804.
15. V. Ruppert, T. Meyer, C. Struwe, J. Petersen, A. Perrot, M.G. Posch, et al., Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy, Eur. J. Hum. Genet. 18 (2010) 694-699.
16. C.E. Angermann, S. Stork, G. Gelbrich, H. Faller, R. Jahns, S. Frantz, et al., Mode of action and effects of standardized collaborative disease management onmortality and morbidity in patients with systolic heart failure: The Interdisciplinary Network for Heart Failure (INH) study, Circ. Heart Fail. 5 (2011) 25-35.
17. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, et al., 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation, Circulation 119 (2009) e391-e479.
18. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, et al., Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology, J. Am. Soc. Echocardiogr. 18 (2005) 1440-1463.
19. R.B. Devereux, D.R. Alonso, E.M. Lutas, G.J. Gottlieb, E. Campo, I. Sachs, et al., Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings, Am. J. Cardiol. 57 (1986) 450-458.
20. W.J. Paulus, C. Tschope, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, F.E. Rademakers, et al., How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology, Eur. Heart J. 28 (2007) 2539-2550.
21. F. Harrel, Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, Springer, New York, 2001.
22. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth, A more accuratemethod to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group, Ann. Intern. Med. 130 (1999) 461-470.
23. S.C. Stamou, M. Nussbaum, R.M. Stiegel, M.K. Reames, E.R. Skipper, F. Robicsek, et al., Effect of body mass index on outcomes after cardiac surgery: Is there an obesity paradox? Ann. Thorac. Surg. 91 (2011) 42-47.
24. A. Oreopoulos, R. Padwal, C.M. Norris, J.C. Mullen, V. Pretorius, K. Kalantar-Zadeh, Effect of obesity on short- And long-term mortality postcoronary revascularization: A meta-analysis, Obesity (Silver Spring) 16 (2008) 442-450.
25. J. Niedziela, B. Hudzik, N. Niedziela, M. Gasior, M. Gierlotka, J.Wasilewski, et al., The obesity paradox in acute coronary syndrome: A meta-analysis, Eur. J. Epidemiol. 29 (2014) 801-812.
26. J.C. Seidell, T.L. Visscher, Body weight and weight change and their health implications for the elderly, Eur. J. Clin. Nutr. 54 (Suppl. 3) (2000) S33-S39.
27. K.M. Flegal, B.I. Graubard, D.F. Williamson, M.H. Gail, Excess deaths associated with underweight, overweight, and obesity, JAMA 293 (2005) 1861-1867.
28. S. Kenchaiah, S.J. Pocock, D. Wang, P.V. Finn, L.A. Zornoff, H. Skali, et al., Body mass index and prognosis in patients with chronic heart failure: Insights from the Candesartan in Heart failure: Assessment of reduction in mortality and morbidity (CHARM) program, Circulation 116 (2007) 627-636.
29. S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, et al., Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study, Lancet 361 (2003) 1077-1083.
30. E.L. Richman, M.J. Stampfer, Weight loss and mortality in the elderly: separating cause and effect, J. Intern. Med. 268 (2010) 103-105.
31. C. Adamopoulos, P. Meyer, R.V. Desai, K. Karatzidou, F. Ovalle, M.White, et al., Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: A propensity-matched study, Eur. J. Heart Fail. 13 (2011) 200-206.
32. P.A. McAuley, K.M. Beavers, Contribution of cardiorespiratory fitness to the obesity paradox, Prog. Cardiovasc. Dis. 56 (2014) 434-440.
33. E.E. Calle, M.J. Thun, J.M. Petrelli, C. Rodriguez, C.W. Heath Jr., Body-mass index and mortality in a prospective cohort of U.S. adults, N. Engl. J. Med. 341 (1999) 1097-1105.
34. A. Schatzkin, E. Slud, Competing risks bias arising from an omitted risk factor, Am. J. Epidemiol. 129 (1989) 850-856.
35. M.C. Pardo Silva, C. De Laet, W.J. Nusselder, A.A. Mamun, A. Peeters, Adult obesity and number of years lived with and without cardiovascular disease, Obesity (Silver Spring) 14 (2006) 1264-1273.
36. G. Montalescot, U. Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, et al., 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology, Eur. Heart J. 34 (2013) 2949-3003.
37. L. Tavazzi, A.P. Maggioni, R.Marchioli, S. Barlera, M.G. Franzosi, R. Latini, et al., Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial, Lancet 372 (2008) 1231-1239.
38. C.Wanner, V. Krane, W. Marz, M. Olschewski, J.F.Mann, G. Ruf, et al., Atorvastatin in patients with type 2 diabetesmellitus undergoing hemodialysis, N. Engl. J.Med. 353 (2005) 238-248.
39. A. Sandek, I. Bjarnason, H.D. Volk, R. Crane, J.B. Meddings, J. Niebauer, et al., Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure, Int. J. Cardiol. 157 (1) (2012) 80-85.
40. R. Sharma, S. von Haehling, M. Rauchhaus, A.P. Bolger, S. Genth-Zotz, W. Doehner, et al., Whole blood endotoxin responsiveness in patients with chronic heart failure: The importance of serum lipoproteins, Eur. J. Heart Fail. 7 (2005) 479-484.
41. S. von Haehling, J.C. Schefold, J. Springer, S.D. Anker, The cholesterol paradox revisited: Heart failure, systemic inflammation, and beyond, Heart Fail. Clin. 4 (2008) 141-151.
42. G.A. Kaysen, J.P. Eiserich, Characteristics and effects of inflammation in end-stage renal disease, Semin. Dial. 16 (2003) 438-446.
43. T. Horwich, Low-density lipoprotein in the setting of congestive heart failure: Is lower really better? Curr. Atheroscler. Rep. 11 (2009) 343-349.
44. C.P. Kovesdy, J.E. Anderson, K. Kalantar-Zadeh, Inverse association between lipid levels andmortality inmenwith chronic kidney diseasewho are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome, J. Am. Soc. Nephrol. 18 (2007) 304-311.
45. U. Ravnskov, High cholesterol may protect against infections and atherosclerosis, QJM 96 (2003) 927-934.
46. K.H. Cho, M.H. Jeong, Y. Ahn, Y.J. Kim, S.C. Chae, T.J. Hong, et al., Low-density lipoprotein cholesterol level in patients with acutemyocardial infarction having percutaneous coronary intervention (the cholesterol paradox), Am. J. Cardiol. 106 (2010) 1061-1068.
47. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, J.H. Cornel, et al., Rosuvastatin in older patients with systolic heart failure, N. Engl. J. Med. 357 (2007) 2248-2261.
48. P. Deedwania, P. Barter, R. Carmena, J.C. Fruchart, S.M. Grundy, S. Haffner, et al., Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the treating to new targets study, Lancet 368 (2006) 919-928.
49. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al., Intensive versusmoderate lipid loweringwith statins after acute coronary syndromes, N. Engl. J. Med. 350 (2004) 1495-1504.
50. S. Bangalore, F.H.Messerli, F.S. Ou, J. Tamis-Holland, A. Palazzo, M.T. Roe, et al., Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139, 194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative, Am. Heart J. 157 (2009) 525-531.
51. M.Z. Molnar, L.R. Lukowsky, E. Streja, R. Dukkipati, J. Jing, A.R. Nissenson, et al., Blood pressure and survival in long-termhemodialysis patients with and without polycystic kidney disease, J. Hypertens. 28 (2010) 2475-2484.
52. M. Gheorghiade, W.T. Abraham, N.M. Albert, B.H. Greenberg, C.M. O'Connor, L. She, et al., Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure, JAMA 296 (2006) 2217-2226.
53. E. Lacson Jr., J.M. Lazarus, The association between blood pressure and mortality in ESRD-not different from the general population? Semin. Dial. 20 (2007) 510-517.